ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.

Product information

CAS Number: 855291-54-2

Molecular Weight: 320.39

Formula: C19H20N4O

Chemical Name: 5-{6-[(3R)-1-azabicyclo[2.2.2]octan-3-yloxy]pyridazin-3-yl}-1H-indole

Smiles: C1[C@H](OC2=CC=C(N=N2)C2=CC=C3NC=CC3=C2)C2CCN1CC2

InChiKey: LUKNJAQKVPBDSC-SFHVURJKSA-N

InChi: InChI=1S/C19H20N4O/c1-2-16-15(5-8-20-16)11-14(1)17-3-4-19(22-21-17)24-18-12-23-9-6-13(18)7-10-23/h1-5,8,11,13,18,20H,6-7,9-10,12H2/t18-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (312.12 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

ABT-107 exhibits good bioavailability in mouse (orally, 51.1%; intraperitoneally,100%), rat (orally, 81.2%; intraperitoneally, 100.0%), and monkey (orally, 40.6%; intramuscularly, 100%), and good CNS penetration in rodents with a brain/plasma ratio of 1. ABT-107 (0.01-1 μmol/kg i.p., 15 min before sacrifice) produces a dose-dependent increase in ERK1/2 and CREB. ABT-107 (0.01, 0.1, and 1.0 mg/kg i.p.) increases S9-GSK3 and decreases p-tau in mouse cortex and hippocampus in mice. ABT-107 (5 mg/kg/day i.p.) infusion attenuates tau hyperphosphorylation in AD transgenic APP-tau mice.

Products are for research use only. Not for human use.